Merck KGaA Just Dropped $11.3 Billion on the Lab Supply Store
Merck KGaA is spending $11.3 billion in cash to buy Bio-Techne, the company behind 400,000 antibody types and 6,000 proteins used in labs worldwide. It's one of the biggest life sciences tools deals of the year, and analysts are split on whether the hefty price tag will pay off.
The Biggest Shopping Spree in Life Sciences This Year
Imagine walking into a Home Depot, but instead of lumber and power tools, the shelves are stacked with thousands of different proteins, antibodies, and biological testing kits. Now imagine buying the entire store for $11.3 billion in cash.
That's essentially what Merck KGaA just did.
The German conglomerate agreed to acquire Bio-Techne, a Minneapolis-based life sciences tools company, for $73 per share. The all-cash deal values Bio-Techne at roughly $11.3 billion in enterprise value (about EUR 9.9 billion), making it one of the largest biotech tools acquisitions of the year. Shareholders already approved the merger in September, and closing is expected in late 2026 or early 2027.
The offer carried a 36% premium to Bio-Techne's one-month volume-weighted average trading price. That's a hefty markup, and it tells you something important: Merck KGaA really wanted this company.
So What Does Bio-Techne Actually Make?
Bio-Techne doesn't make drugs. It makes the stuff that helps other companies make drugs. Think of it as the picks-and-shovels play in a biotech gold rush.
The company operates in two main segments. Protein Sciences is the big one, pulling in $870 million in fiscal 2025, or about 72% of total revenue. This division sells proteins, antibodies, and testing kits that researchers use every single day in labs around the world. The second segment, Diagnostics and Spatial Biology, brought in $346 million and covers more specialized tools for disease detection and tissue analysis.
All together, Bio-Techne posted $1.22 billion in revenue for fiscal 2025, up about 5% from the prior year. Not explosive growth, but the kind of steady, recurring revenue that acquirers love. Labs don't stop buying reagents (the chemical ingredients used in experiments) just because the economy gets bumpy. It's like a subscription business, except the subscribers are scientists who literally can't do their jobs without your products.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The company also rolled out over 400 new products in fiscal 2025 alone, which tells you the innovation engine is humming.
Why Merck KGaA Is Writing the Check
Merck KGaA (not to be confused with Merck & Co., the U.S. pharma giant) has been on a deliberate shopping spree in life sciences for years. The company already operates MilliporeSigma, its U.S. and Canadian life sciences arm, which sells everything from lab chemicals to bioprocessing equipment.
But the strategy isn't random diversification. It's focused capability-building. In 2024, Merck picked up Mirus Bio to strengthen its position in transfection reagents, a key ingredient in manufacturing viral vectors for cell and gene therapies. It also acquired HUB Organoids Holding, adding mini-organ technology to its toolkit.
The pattern is clear: Merck wants to be the one-stop shop for every step of drug discovery and manufacturing. Bio-Techne fills a massive gap in that ambition, especially on the protein sciences and reagent side. Merck has publicly said that for larger future deals, life sciences is the priority arena. This deal is the loudest proof of that commitment yet.
The company expects to wring out EUR 140 million in cost synergies (that's corporate-speak for savings from combining overlapping operations) within three years. The deal is being funded through a mix of existing cash on hand and new debt.
Wall Street's Verdict: Cautiously Impressed
Analyst reactions have been mixed to cautious, which in Wall Street terms basically means "we see the logic, but the price tag makes us nervous."
On the positive side, the strategic fit is hard to argue with. Bio-Techne's product portfolio slots neatly into Merck's existing life sciences platform, and the deal could meaningfully reshape the company's revenue mix toward higher-growth areas.
The skepticism centers on three things. First, the price looks rich. Several analyst notes describe the offer as near-full value, which leaves very little room for error. Second, there's execution risk: integrating a $1.2 billion revenue business is never simple, and preserving Bio-Techne's culture and customer relationships while extracting synergies is a delicate balancing act. Third, some analysts worry the new debt could pressure Merck's margins in the near term.
Bio-Techne's stock was trading around $59.90 on October 9. With the offer at $73, the spread between the market price and the deal price tells you something about how the market was valuing the company before the acquisition premium. The $230 million termination fee Bio-Techne would owe if it walks away only reinforces confidence that this deal closes.
The Bigger Picture: Lab Tools Are Hot
This deal isn't happening in a vacuum. The life sciences tools sector has been in full consolidation mode throughout 2025 and 2026.
Waters grabbed BD's biosciences and diagnostics units for a staggering $17.5 billion, the biggest pure tools deal in recent memory. Thermo Fisher spent $8.9 billion on Clario to beef up its clinical trial data capabilities. Even smaller players are getting swept up: Advanced Instruments bought Nova Biomedical for $2.2 billion, and Bio-Rad acquired Stilla for $275 million.
The logic driving all of this is pretty straightforward. Drug development is getting more complex (think cell therapies, gene editing, personalized medicine), and the companies supplying the tools for that work are becoming more valuable. It's the same reason NVIDIA became a trillion-dollar company; when everyone's building AI, the company selling the chips wins regardless of whose AI turns out best.
For Merck KGaA, the bet is that the biotech industry's demand for high-quality proteins, antibodies, and reagents will only grow. By owning Bio-Techne, they're not just buying revenue. They're buying a seat at every lab bench in the world.
What Happens Next
The deal still needs regulatory approvals, though shareholders have already given it the green light. If all goes according to plan, Bio-Techne will become part of Merck KGaA by early 2027 at the latest.
The real question isn't whether the deal closes. It's whether Merck can justify the premium. EUR 140 million in synergies sounds nice on a slide deck, but delivering those savings while keeping Bio-Techne's product engine firing on all cylinders is the hard part. History is littered with acquirers who paid top dollar for great companies and then fumbled the integration.
For now, though, Merck KGaA just made the boldest statement in life sciences tools this year. They bought the whole store, and they paid cash.
4 min read
Foghorn Blew Through $300M of Lilly's Cash and Has Nothing to Show for It
Foghorn Therapeutics axed 40% of its workforce after its Eli Lilly-partnered cancer drug flopped in Phase 1. The $1.6 billion collaboration is over, the stock is at $2, and the wreckage tells a cautionary tale about one of oncology's trickiest frontiers.
